Heart failure & cardiomyopathies

Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial

Eur Heart JPublished Secondary analysis of the ADVOR randomised trial

Authors' conclusion

Acetazolamide is associated with a higher rate of successful decongestion across the entire range of renal function with more pronounced effects regarding natriuresis and diuresis in patients with a lower eGFR. While WRF occurred more frequently with acetazolamide, this was not associated with adverse clinical outcomes.

Study context

Population
Patients with acute decompensated HF (acute decompensated heart failure (ADHF)); median estimated glomerular filtration rate (eGFR) 40 (30–52) mL/min/1.73 m² on admission
Participants
519 patients
Comparison
IV acetazolamide vs placebo on top of IV loop diuretics, by baseline renal function
Primary endpoint
Decongestion, diuresis, natriuresis and clinical outcomes according to baseline renal function; changes in renal function
Methodological detailspre-specified analysis, placebo-controlled
  • Pre-specified analysis
  • Placebo-controlled

Primary result

As reported in the abstract

Effect of acetazolamide across baseline eGFR (subgroups)
Acetazolamide consistently increased likelihood of decongestion across entire eGFR spectrum
P-interaction = .977
Natriuresis and diuresis higher with acetazolamide, with higher treatment effect at low eGFR
both P-interaction < .007

Further findings

Worsening renal function (WRF) with acetazolamide not associated with higher incidence of HF hospitalizations and mortality
P for interaction = 0.467
Decongestion at discharge associated with fewer adverse clinical outcomes irrespective of WRF
P for interaction = 0.805

Safety

Worsening renal function (rise in creatinine ≥ 0.3 mg/dL) · treatment period

P < 0.001

Creatinine · 3 months

No difference in creatinine after 3 months
P = 0.565

Original publication

Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial. Eur Heart J. Published 25 August 2023. doi:10.1093/eurheartj/ehad557

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.